FEMY
Femasys Inc. NASDAQ Listed Jun 18, 2021$2.10
-2.78%
vs $2.16
Mkt Cap $83.1M
52w Low $0.34
24.4% of range
52w High $7.56
50d MA $2.74
200d MA $1.77
P/E (TTM)
-0.5x
EV/EBITDA
—
P/B
14.2x
Debt/Equity
0.8x
ROE
-317.4%
P/FCF
-4.3x
RSI (14)
19.60
ATR (14)
$0.18
Beta
-2.28
50d MA
$2.74
200d MA
$1.77
Avg Volume
159.6K
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
3950 Johns Creek Court · Suwanee, GA 30024 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | AMC | -1.33 | 0.10 | +107.3% | 8.60 | +0.0% | -6.0% | -6.7% | +1.2% | -0.3% | -6.3% | — |
| Mar 31, 2026 | AMC | -1.67 | -0.20 | +88.0% | 0.42 | +2.9% | -0.8% | +5.3% | -2.2% | -8.6% | +1.3% | — |
| Nov 14, 2025 | AMC | -0.12 | -0.10 | +13.0% | 0.90 | -4.2% | -11.3% | -9.6% | +5.4% | +5.5% | +15.0% | — |
| Aug 8, 2025 | AMC | -0.18 | -0.16 | +11.1% | 0.89 | -7.0% | -13.2% | -5.9% | +5.0% | -3.1% | -4.4% | — |
| May 8, 2025 | AMC | -0.17 | -0.23 | -35.3% | 1.15 | -1.7% | -7.8% | +1.9% | +1.9% | -4.5% | +1.9% | — |
| Mar 27, 2025 | AMC | -0.18 | -0.23 | -24.3% | 1.34 | -2.2% | -3.7% | -3.1% | -1.6% | +4.9% | -4.7% | — |
| Nov 12, 2024 | AMC | -0.20 | -0.24 | -20.0% | 1.03 | +4.9% | +0.0% | -4.9% | -2.8% | -2.2% | -4.9% | — |
| Aug 8, 2024 | AMC | -0.18 | -0.21 | -16.7% | 0.86 | +4.6% | +8.1% | +12.9% | +3.8% | -2.8% | +3.8% | — |
| May 9, 2024 | AMC | -0.22 | -0.17 | +22.7% | 1.27 | +0.8% | -4.7% | +5.0% | +8.7% | -3.6% | -3.0% | — |
| Mar 28, 2024 | AMC | -0.19 | -0.19 | +0.0% | 1.55 | -0.6% | +11.0% | +1.2% | +4.0% | -5.5% | -1.2% | — |
| Nov 14, 2023 | AMC | -0.25 | -0.26 | -4.0% | 0.93 | +18.3% | +8.6% | -8.9% | +4.9% | -1.5% | -5.1% | — |
| Aug 10, 2023 | AMC | -0.19 | -0.22 | -14.3% | 0.43 | -6.0% | +0.0% | -1.4% | -2.8% | -2.9% | +0.7% | — |
| May 11, 2023 | AMC | -0.26 | -0.25 | +3.8% | 0.86 | -3.8% | -13.2% | -3.6% | +1.7% | +5.5% | +2.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.89 | $0.83 | -7.0% | -13.2% | -5.9% | +5.0% | -3.1% | -4.4% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.89 | $0.90 | +1.7% | +10.7% | +0.3% | -0.3% | -1.4% | -2.9% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.80 | $0.80 | +0.0% | +6.3% | +8.8% | -3.9% | +2.3% | -1.1% |
| May 13 | Jones Trading | Maintains | Buy → Buy | — | $1.08 | $1.07 | -0.9% | +1.9% | -4.5% | +1.9% | -0.9% | -1.9% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.15 | $1.13 | -1.7% | -7.8% | +1.9% | +1.9% | -4.5% | +1.9% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.34 | $1.31 | -2.2% | -3.7% | -3.1% | -1.6% | +4.9% | -4.7% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.54 | $1.57 | +1.9% | +1.9% | +1.9% | +0.0% | -2.5% | +2.6% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.60 | $1.56 | -2.5% | -3.8% | +1.9% | +1.9% | +0.0% | -2.5% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.46 | $1.51 | +3.4% | -4.1% | +12.1% | +1.9% | -3.7% | +1.9% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.58 | $1.64 | +3.8% | +4.4% | -3.6% | -1.3% | -1.9% | -1.9% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.16 | $1.20 | +3.4% | +7.8% | +5.6% | +4.5% | +15.2% | -0.6% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.10 | $1.10 | +0.0% | -1.8% | +2.8% | -0.9% | +1.8% | +1.8% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.06 | +0.0% | -1.9% | +7.7% | -1.8% | -1.8% | +2.8% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $1.03 | $1.08 | +4.9% | +0.0% | -4.9% | -2.8% | -2.2% | -4.9% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.17 | $1.13 | -3.4% | -12.0% | +0.0% | -4.9% | -2.8% | -2.2% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.36 | $1.36 | +0.0% | -2.2% | -5.3% | -6.3% | +1.7% | -6.7% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.15 | $1.21 | +5.2% | -2.6% | +0.0% | +0.0% | -2.7% | +2.8% |
| Aug 14 | Chardan Capital | Maintains | Buy → Buy | — | $1.09 | $1.11 | +1.8% | -2.8% | +3.8% | -0.9% | -2.8% | -5.7% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.86 | $0.90 | +4.6% | +8.1% | +12.9% | +3.8% | -2.8% | +3.8% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.95 | $1.02 | +6.8% | +33.0% | -9.4% | +1.7% | -6.8% | -4.6% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.34 | -3.6% | -8.6% | -4.7% | +5.0% | +8.7% | -3.6% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.55 | $1.54 | -0.6% | +11.0% | +1.2% | +4.0% | -5.5% | -1.2% |
| Apr 1 | Chardan Capital | Maintains | Buy → Buy | — | $1.55 | $1.54 | -0.6% | +11.0% | +1.2% | +4.0% | -5.5% | -1.2% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.80 | +0.0% | -4.4% | -3.5% | -3.0% | -6.8% | -2.0% |
| Mar 21 | Chardan Capital | Maintains | Buy → Buy | — | $1.80 | $1.80 | +0.0% | -4.4% | -3.5% | -3.0% | -6.8% | -2.0% |
| Mar 20 | JonesTrading | Maintains | Buy → Buy | — | $2.00 | $1.87 | -6.5% | -10.0% | -4.4% | -3.5% | -3.0% | -6.8% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.04 | $1.04 | +0.0% | -10.6% | +8.6% | -8.9% | +4.9% | -1.5% |
| Sep 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.88 | +23.7% | +96.1% | +30.5% | -36.0% | -8.0% | -9.2% |
| Sep 26 | JonesTrading | Maintains | Buy → Buy | — | $0.33 | $1.22 | +267.9% | +346.3% | -25.0% | +36.9% | +96.1% | +30.5% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $0.43 | $0.40 | -6.0% | +0.0% | -1.4% | -2.8% | -2.9% | +0.7% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.46 | $0.44 | -4.3% | -6.5% | +0.0% | -1.4% | -2.8% | -2.9% |
| Jul 3 | Chardan Capital | Maintains | Buy → Buy | — | $0.51 | $0.55 | +7.8% | -3.5% | +2.4% | +1.4% | +0.8% | -8.7% |
| Mar 31 | Chardan Capital | Maintains | Buy → Buy | — | $1.15 | $1.04 | -9.6% | -5.2% | +2.8% | +0.0% | -5.4% | +5.7% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $1.24 | $1.20 | -3.2% | -2.4% | +3.3% | +0.0% | +0.0% | -2.4% |
| Oct 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.23 | $1.29 | +4.9% | -5.7% | -9.5% | +1.0% | +33.0% | -2.1% |
| Jun 17 | Maxim Group | Maintains | Buy → Buy | — | $1.30 | $1.47 | +13.1% | +10.0% | +2.8% | +0.7% | +4.1% | +22.1% |
| Mar 25 | Chardan Capital | Maintains | Buy → Buy | — | $2.31 | $2.17 | -6.1% | -3.9% | +0.0% | +5.0% | -1.3% | -1.7% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.35 | $2.47 | +5.1% | -1.7% | -3.9% | +0.0% | +5.0% | -1.3% |
| Jul 13 | JonesTrading | Maintains | Buy → Buy | — | $7.41 | $7.87 | +6.2% | +14.7% | -11.8% | -2.7% | +2.6% | -6.7% |
| Jul 13 | Chardan Capital | Maintains | Buy → Buy | — | $7.41 | $7.87 | +6.2% | +14.7% | -11.8% | -2.7% | +2.6% | -6.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Lee-Sepsick Kathy | Chief Executive Officer | Buy | 15,625 | $3.20 | $50K | 15,625 | +0.00% | +1.85% |
| Aug 7, 2026 | Elefant Dov | Chief Financial Officer | Buy | 15,625 | $3.20 | $50K | 15,625 | +0.00% | +1.85% |
| Aug 7, 2026 | Canning John Charles | Chief Operating Officer | Buy | 4,375 | $3.20 | $14K | 4,375 | +0.00% | +1.85% |
| Aug 7, 2026 | Sipos Jeremy Alexander | Chief Technology Officer | Buy | 3,125 | $3.20 | $10K | 3,125 | +0.00% | +1.85% |
| Aug 7, 2026 | Mifek Jeffrey Gerald | Chief Clinical-Medical Affairs | Buy | 3,125 | $3.20 | $10K | 3,125 | +0.00% | +1.85% |
8-K · 8.01
!! High
Femasys Inc. -- 8-K 8.01: Material Event / Announcement
Jun 24
8-K · 7.01
! Medium
Femasys Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 4
8-K
Femasys Inc. -- 8-K Filing
I appreciate the request, but the summary provided doesn't contain substantive information about a material event, deal outcome, or development affecting Femasys Inc. (FEMY) that would warrant an investor-focused analysis. Please provide a summary with actual details about the filing's content.
Apr 29
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
New executive Mr. Canning's 150,000-share option grant signals management confidence but dilutes existing shareholders and suggests the company needed external talent to drive performance improvements.
Apr 1
8-K
Unknown — 8-K Filing
Femasys is advancing its FemBloc contraceptive device toward FDA approval through an ongoing pivotal trial, signaling progress on a potentially significant revenue driver that could validate the company's core business strategy.
Mar 31
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
FEMY's unexpected executive departure effective March 18, 2026, signals potential leadership instability that could disrupt strategic execution and warrant investor caution until successor qualifications are clarified.
Mar 20
Institutional (13F) — Top 12
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Fiduciary Trust Co | 249,876 | $105K | New | Mar 2026 |
| 2 | Jane Street Group, Llc | 107,003 | $62K | New | Dec 2025 |
| 3 | Northern Trust Corp | 118,411 | $50K | Added | Mar 2026 |
| 4 | Ubs Group Ag | 61,929 | $26K | Reduced | Mar 2026 |
| 5 | Wealthspire Advisors, Llc | 28,134 | $12K | — | Mar 2026 |
| 6 | Northwestern Mutual Wealth Management Co | 20,000 | $12K | — | Dec 2025 |
| 7 | Hrt Financial Lp | 26,738 | $11K | Reduced | Mar 2026 |
| 8 | Aljian Capital Management, Llc | 25,268 | $11K | — | Mar 2026 |
| 9 | Pandora Wealth, Inc. | 15,000 | $9K | — | Dec 2025 |
| 10 | Kestra Private Wealth Services, Llc | 15,000 | $6K | New | Mar 2026 |
| 11 | Cx Institutional | 750 | $3K | Reduced | Jun 2026 |
| 12 | Ifp Advisors, Inc | 1,000 | $306 | — | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 221,277 | $126K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 135,909 | $57K | Mar 2026 |
| 3 | Fidelity Series Total Market Index Fund | 76,588 | $30K | May 2026 |
| 4 | Fidelity Total Market Index Fund | 50,540 | $20K | May 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 18,182 | $10K | Feb 2026 |
Valuation
Market Cap
$83.1M
Enterprise Value
$77.0M
P/E (TTM)
-0.46x
Forward P/E
—
PEG Ratio
0.03x
P/B
14.15x
P/S
36.12x
P/FCF
-4.32x
EV/EBITDA
—
Shares Out
39.5M
Financials (TTM)
Revenue
$2.3M
Net Income
-$12.3M
EBITDA
-$9.8M
Free Cash Flow
-$19.2M
Op Cash Flow
-$18.7M
EPS Basic
$-0.47
EPS Diluted
$-4.57
EPS Forward
$-0.31
Gross Margin
52.2%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$20.7M
Total Liab.
$14.9M
Total Equity
$5.9M
Cash
$9.3M
LT Debt
$3.2M
Book Value/Sh
$0.15
Debt/Equity
0.80x
Current Ratio
4.53
Quick Ratio
2.95
Returns & Growth
ROE
-317.4%
ROA
-89.9%
ROIC
-100.1%
Rev Growth YoY
+40.8%
EPS Growth YoY
+44.0%
Price Returns
2W
-15.0%
1M
-33.7%
3M
-50.3%
6M
-74.1%
12M
-71.2%
Technicals
52W High
$7.56
52W Low
$0.34
50d MA
$2.74
200d MA
$1.77
RSI (14)
19.60
ATR (14)
$0.18
Beta
-2.28
Avg Volume
160K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 8:51am
· Source: financialmodelingprep.com